NLRP3 inflammasome respond to particular danger signals and induced disease-specific inflammation, which is regarded as an attractive target for reducing pathological inflammation in human diseases. We established disease-specific inflammatory cell and mice models for screening the ingredients or drugs with NLRP3 inflammasome inhibition potential, targeted to specific disease indications.

Lipopolysaccharide is commonly used to induce inflammation in traditional anti-inflammatory drug screening platform; however, lipopolysaccharide is not a particular medically relevant stimulator, limited its application in preclinical development. We established a NLRP3 inflammasome-based particular medically relevant screening platform for anti-inflammatory drug development.

NLRP3 inflammasome-based disease-specific anti-inflammatory drug screening and testing platform helps food and biomedical industry partners developing bioactive components in prevention or treatment inflammatory disease. The platform helps industry partners to reduce time and cost of R&D. We collaborated with biotech companies to develop NLRP3 inflammasome inhibitor and helps them to get patents.